No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia.
P L IshøyB FagerlundB V BrobergN BakF K KnopB Y GlenthøjBjørn H EbdrupPublished in: Acta psychiatrica Scandinavica (2017)
The non-significant results of this first clinical trial exploring non-metabolic effects of a long-acting GLP-1RA in patients with schizophrenia could reflect a general problem of translating cognitive-enhancing effects of GLP-1RAs from animals to humans or be explained by factors specifically related to schizophrenia spectrum patients with obesity such as antipsychotic treatment.
Keyphrases
- clinical trial
- weight loss
- metabolic syndrome
- type diabetes
- bipolar disorder
- insulin resistance
- rheumatoid arthritis
- adipose tissue
- study protocol
- open label
- randomized controlled trial
- weight gain
- phase ii
- ankylosing spondylitis
- obese patients
- body mass index
- combination therapy
- high fat diet induced
- physical activity
- disease activity
- replacement therapy
- binding protein